SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Fridays selloff and the Black Monday anniversary fueled crash fears, but a sharp futures rebound prompted bulls to call the panic overblown and point to short covering and earnings; bears remained wary of a failed bounce and continued weakness in tech and AI stocks.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Q3 earnings are the central focus, with traders debating whether margins and cash flow can hold and whether managements robotaxi and AI plans justify confidence despite strong deliveries. The Roadster demo drew both praise and skepticism, but many traders say it does little to resolve concerns ahead of the results.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after a sharp share-price drop amid broad biotech weakness and options-expiration volatility, while investors await the 80th-event trigger and final analysis of the Phase 3 REGAL trial of GPS. Bulls view the extended wait since the last reported event as possible evidence of longer patient survival; bears point to the delay and company silence as reasons for concern, with neither interpretation confirmed.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp selloff in AI- and semiconductor-linked stocks has pressured QQQ, with traders debating whether concerns about AI spending and debt signal a broader correction or an oversold pullback. Crash warnings have been met by dip-buying and hopes for a rebound, leaving sentiment divided ahead of major tech earnings.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trumps waiver of Russia-related sanctions and tariffs dominates discussion, with traders criticizing the move as favorable to Putin and questioning its political and market implications. Some defend it as a way to ease energy costs, while bearish comments also point to DJTs recent lows and concerns about the companys business performance.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data for Iovances lifileucel-plus-Keytruda combination in first-line melanoma is driving attention, with traders highlighting response depth and durability as potential support for expanding beyond advanced melanoma. Others caution that the results come from a small cohort and may reflect an earlier data cut, so the ongoing Phase 3 TILVANCE-301 trial is seen as the key test; some also attribute the share decline to broader biotech weakness.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins pullback and choppy trading near a closely watched support zone are driving discussion, with traders pointing to leveraged long liquidations and recent ETF outflows as signs of pressure. The community is split between expecting support to hold and a short squeeze, and warning that a breakdown could extend the decline.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention as small caps sell off amid hotter-than-expected inflation data and worries that the Fed may keep rates higher or hike again, pressuring companies sensitive to borrowing costs. Traders are debating whether oversold conditions and support levels could spark a bounce, while others cite technical breakdowns and put buying as signs of continued weakness.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Crudes rally amid fears of supply and shipping disruptionsespecially tanker attacks and constrained Strait of Hormuz flows, alongside Russia-Ukraine energy risksis driving attention to USO. Bulls see a persistent supply shock, while bears argue the rally includes a geopolitical premium that could unwind if tensions ease or a deal emerges.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

EROCs large Anthropic order and Meta-linked data-center power project are driving discussion of its growing backlog and role in supplying natural-gas microgrids amid grid constraints; bullish traders are focused on whether upcoming results show the contracts converting into revenue. Skeptics point to execution and CEO concerns, while others debate the stocks sharp swings and short interest.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can-Fite’s Liver Cancer Trial Just Got More Interesting and the FDA Clock Matters Now

Can-Fite BioPharma (NYSEAMERICAN:CANF) has put a potentially important new marker on the radar for its late-stage liver-cancer program: patients in the company’s ongoing pivotal Phase III study of Namodenoson are living longer than anticipated across the blinded study population.

AI, Clinical Data, and Regulatory Catalysts have Wall Street Watching These Biotechs

Three emerging biotechnology companies, Can-Fite BioPharma (NYSEAMERICAN:CANF), NeOnc Technologies (NASDAQ:NTHI), and PMGC Holdings (NASDAQ:ELAB) through its NorthStrive Biosciences subsidiary, are pursuing a distinct therapeutic strategy, the common theme is execution. Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the second half of 2026.

Why Is CANF Stock Surging Today?

Equity

Can-Fite said Namodenoson met the Phase IIa study's main safety goal and demonstrated durable overall survival.

CANF Stock Pulls Back After Patent-Fueled Surge – Retail Calls It Consolidation Ahead Of Next Leg Up

Can-Fite BioPharma announced it has received a patent in Japan for its obesity therapy.

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

Power, Compute and Breakthrough Science

Today’s headlines underscore a decisive shift toward owning the infrastructure, power, and materials that will underpin the next phase of the AI economy, including $KBLB, $VCIG, $CANF, $ASNS, $BW, and $APLD

Why Did CANF Stock Soar 25% Today?

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

This Microcap Just Locked Up New IP in a Massive Pharma Market

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The ...

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Can-Fite Biopharma Ltd - ADR

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Can-Fite BioPharma Ltd.

$CANF this trash ponzi company won’t give a shiiettt if it go to zero  because they already scammed over $400 millions from investor in the last 5 years and they won big time lmao. They willl keep dilution and scam as much as possible until stock go to zero.  It’s an Epic loophole. Hahaha

Donnie chen

$CANF 13000 fake paid scam accounts smh , all these paid trash watchers prob paid by canf in China opening multiples account promote this PONZI scam stock non stop !!! Reverse split and dilution offering loke 20 times  the last 5 years.   They fuking dilution and scam investors like over $400,000,000 so far SmH !!!!!!!

$CANF just checking back lmao …. This stock sold all the longs SOuLs… epic Ponzi scam stock of the century.   Stay away from this trash scamming investing in the last 5-1” years.   Alll they do is dilution offering and reverse split like 1000 times non stop !!!!!!!         All you longs are dumb and stupid with NoN stop stupid egos lmao ….. 🤣 this stock is dead and WILL do another SCAM reverse split yet again lmao 🤣.   Idiots with big egos keep buying this trash for years smh

$CANF dude what a worry, shorter bear or something ??  the float is increase recently to about 6 million of where do you get this reverse split from… Why is everybody a scumbag?

Joeejet

$CANF Never bought an ADR. is the 1.90 for 1 share or 2? Anyone know the ADR fee  Schwab charges?

Feed

News

Sentiment

Fundamentals

Info

CANF Can-Fite BioPharma Ltd.

Fundamentals

Latest CANF News